Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (December 2008)

35 slides from Ardea Biosciences's corporate update, Dec 18, 2008

  1. Slide 1: December 2008 Company Update

    December 2008 Company Update Barry D. Quart, PharmD President & Chief Executive Officer

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Information Regarding Disclosures

    Information Regarding Disclosures The Common Stock being offered in the offering (the "Offering") has not and will not be registered under the Securities Act of 1933, as amended (the "Act"), or under any state securities laws nor has the Securities and Exchange Commission (the "Commission") or any s

  4. Slide 4: Offering Summary

    Issuer: Ardea Biosciences, Inc. Ticker: NASDAQ: RDEA Amount: $25 -$30 million Security: Common Stock Offering Format: All-Insider PIPE Use of Proceeds: Clinical development Expected Pricing: As soon as possible Placement Agent: Placed by Company Offering Summary 7

  5. Slide 5: Investment Highlights

    9 Investment Highlights Multiple partnering opportunities in early 2009 Anticipate initial efficacy results in gout in early 2009 Phase 2a results with RDEA806 Phase 1 results with RDEA594 Anticipate initiation of Phase 2b with RDEA594 in 1H09, with results in 2H09 Addressing multi-billion-dollar ma

  6. Slide 6: Pipeline Addresses Major Markets

    Pipeline Addresses Major Markets RDEA806 RDEA427 RDEA806 RDEA119 RDEA119 RDEA436 Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV Gout MEKI for Cancer Inflammation Inflammation 11 Gout RDEA594 3rd Gen MEKI + sorafenib for Cancer RDEA119 NNRTI for HIV

  7. Slide 7: HIV Market Opportunity

    HIV Market Opportunity Over $8 billion mature market focused on safety and convenience Highest success rate in Phase 3 of any class Three primary classes of therapies: 10 approved protease inhibitors (PIs) 12 nucleosides (NRTIs; single agents and combinations) Only 4 approved non-nucleosides (NNRTIs

  8. Slide 8: RDEA806 vs. Target Product Profile

    RDEA806 vs. Target Product Profile Highly active against efavirenz-resistant strains High genetic barrier to resistance Better safety profile than efavirenz Reduced CNS toxicity Improved lipid profile Easy to formulate in combination pill Long enough half-life for once daily dosing (10-13 hrs) Can b

  9. Slide 9: HIV Infection Demographics Support Target Product Profile

    HIV Infection Demographics Support Target Product Profile 17 *Estimates Out of 56,300 New Cases in 2006; CDC, New Estimates of HIV Infections

  10. Slide 10: RDEA806 Activity In Vitro Against Resistant NNRTI Viruses

    RDEA806 Activity In Vitro Against Common Resistant NNRTI-Resistant Viruses 19

  11. Slide 11: Phase 2A Median Change in Viral Load

    Days Phase 2A Median Change in Viral Load* Last Dose * Viral load reduction censored in 4 patients who reached 50 copies/ml LOQ of assay and some patients started on triple therapy prior to follow-up visit Percent Patients > 1 log Decrease < 400 copies/ml Placebo 0 0 400 mg BID Capsules - Fasted 100

  12. Slide 12: Safety and Tolerability

    Safety and Tolerability No serious adverse events or premature discontinuations Adverse events generally mild (grade 1) with no required intervention; no grade 3/4 adverse events No indication of CNS toxicity and no drug related rash No clinically significant laboratory abnormalities Reductions in s

  13. Slide 13: Tablet Size Comparisons of Coformulated RDEA806

    Tablet Size Comparisons of Coformulated RDEA806 RDEA806 800 mg + TRUVADA(r) RDEA806 600 mg + TRUVADA(r) ATRIPLA(tm) Sustiva 600 mg + Truvada(r) SUSTIVA(r) 600 mg INTELENCE(tm) 100 mg RDEA806 200 mg 25

  14. Slide 14: No Impact of RDEA806 on Emtricitabine or Tenofovir in Truvada

    No Impact of RDEA806 on Emtricitabine or Tenofovir in Truvada Time (hr) Tenofovir Truvada only dosing Truvada and 800 mg QD RDEA806 x 4 days Time-Concentration Profiles in Plasma Emtricitabine Time (hr) 0.00 0.05 0.10 0.15 0.20 0.25 0 6 12 18 24 30 36 42 48 54 60 66 72 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.

  15. Slide 15: Phase 2b ART Naive Dose Response Efficacy Study

    Study RDEA806-202 Naive Dose Response Study Study Start 1H09 post-partnering Primary Endpoint Proportion of patients with Plasma VL < 50 copies/mL Secondary Endpoints VL decay rate, CD4 and CD8 changes, PK, PK/PD, safety, tolerability, genotypic and phenotypic resistance Location EU/South America/Ca

  16. Slide 16: RDEA427 Has Superior Resistance Profile to Other NNRTIs

    RDEA427 Has Superior Resistance Profile to Other NNRTIs 31

  17. Slide 17: Hyperuricemia/Gout - Unmet Medical Need

    Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease Attacks of severe pain/Inflammation Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (up to 5,000,000 patie

  18. Slide 18: Linear Relationship Between Serum Uric Acid and CRP

    Linear Relationship Between Serum Uric Acid and CRP NHANES III & NHANES 1999-2002 Serum Uric Acid (mg/dl) Log CRP (mg/dL) 2007 ACR Abstract 759 NHANES III n = 18,723 NHANES 99-2002 n = 7,401 Upper 95% CI Lower 95% CI Linear dose-response pattern between sUA and logCRP for sUA concentrations above 4

  19. Slide 19: Competitive Landscape

    Competitive Landscape Allopurinol 40 year old generic xanthine oxidase inhibitor; 21% response rate and 8% SAEs in contemporary study,1 and 0.4% incidence of hypersensitivity, which is 20-25% fatal2 Febuxostat (Takeda) 2nd generation xanthine oxidase inhibitor (more specific than allopurinol) In Pha

  20. Slide 20: RDEA806 Significantly Reduced Serum Uric Acid in Phase 1 MAD Study

    RDEA806 Significantly Reduced Serum Uric Acid in Phase 1 MAD Study 1 0.5 0 - -0.5 - -1 - -1.5 - -2 - -2.5 Day 0 Day 3 Day 7 Day 10/14 Follow-up Change in SUA (mg/dL) Treatment Day Placebo 500 mg bid 400 mg MR bid 300 mg bid - -3 * * * * * * * * * * p<0.001 Serum UA reduction in 2 patients with hyper

  21. Slide 21: Urate Handling in the Nephron

    ~99% Reabsorption Secretion (~50%) Reabsorption (~10% fine tuning) Excretion: Normally ~10-12% of Filtered Load ~100% of uric acid is initially filtered through glomerular filtration Urate Handling in the Nephron URAT1 Enomoto; Urat1 identification in Nature May2002 D Levinson & L Sorensen; Renal Ha

  22. Slide 22: RDEA594, a Metabolite of RDEA806, Responsible for Uric Acid Lowering

    <99% Reabsorption Secretion (~50%) Reabsorption (~10% fine tuning) Increased Excretion ~100% of uric acid is initially filtered through glomerular filtration RDEA594, a Metabolite of RDEA806, is Believed to be Responsible for Uric Acid Lowering URAT1 Enomoto; Urat1 identification in Nature May2002 D

  23. Slide 23: Preliminary Phase 1 Results with RDEA594 are Very Promising

    Preliminary Phase 1 Results with RDEA594 are Very Promising - - 100 0 100 200 300 400 500 RDEA806 IR 300 mg RDEA806 EC Tab 800 mg RDEA594 Sol. 100 mg Preliminary pharmacokinetics of RDEA594 following a single 100 mg oral dose in healthy volunteers shows rapid absorption, a low systemic clearance, an

  24. Slide 24: RDEA594: Lead Product Candidate for Gout

    RDEA594: Lead Product Candidate for Gout RDEA594 inhibits the URAT1 renal transporter, without significant effects on other renal transporters, and it has no antiviral activity RDEA594 is a metabolite of RDEA806 in man and most of the animal species used in toxicology studies Clinical Milestones: In

  25. Slide 25: The Age of Targeted Cancer Treatments

    The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1)* RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 49 *Only MEK inhibitor in clinic witho

  26. Slide 26: RDEA119 is Potent, Highly Specific MEK Inhibitor

    RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK

  27. Slide 27: Sorafenib-Resistant Hepatoma Cells Show Remarkable Response to Combination Therapy

    Sorafenib-Resistant Hepatoma Cells Show Remarkable Response to Combination Therapy Percent Cell Death 53

  28. Slide 28: RDEA119 Synergistic in Combination with Many Other Anti-Cancer Agents

    RDEA119 Synergistic in Combination with Many Other Anti-Cancer Agents Potential Combinations Potential Therapeutic Areas Sorafenib Onyx/Bayer Gemcitabine Lilly Temozolomide Schering Lapatinib GSK AKT inhibitors Merck, Others HCC Melanoma Breast Myeloma Pancreas Renal carcinoma NSCLC Thyroid Colon RD

  29. Slide 29: Pharmacokinetics of RDEA119 Following Multiple Doses in Cancer Patients

    Pharmacokinetics of RDEA119 Following Multiple Doses in Cancer Patients - --25mg/kg BID in Mice - --50 mg/kg QD in Mice Target plasma levels for optimal efficacy from xenograft studies- equals 0.1- 2 ng/ml free drug 1 10 100 1000 0 5 10 15 20 25 Time (hr) 2 mg 4 mg 6 mg 10 mg 20 mg 30 mg 57

  30. Slide 30: RDEA119 is Active in Multiple Models of Inflammatory Disease

    RDEA119 is Active in Multiple Models of Inflammatory Disease Rat paw edema model Collagen-induced arthritis in mice and rats (2008 EULAR) Adjuvant-induced Arthritis (2008 EULAR) Pristane-induced arthritis in rats (2008 EULAR) Monosodium urate crystal (uric acid) induced inflammation (2008 ACR) Trini

  31. Slide 31: AIA Rat Study: RDEA119 more Effective than MTX

    AIA Rat Study: RDEA119 more Effective than MTX Days 13 to 28 61

  32. Slide 32: RDEA119-102 Normal Healthy Volunteer Cytokine Pharmacodynamics

    RDEA119-102 Normal Healthy Volunteer Cytokine Pharmacodynamics 2 Hour 63

  33. Slide 33: Financial Position Summary

    Financial Position Summary Statement of Operations (In thousands, except per share data) Nine Months Ended Sept. 30, 2008 Revenue Operating expenses Interest and other income $ 260 44,074 1,485 NET LOSS $(42,329) NET LOSS PER SHARE $(2.98) 15.0 million common shares outstanding Ended 3Q08 with $30 m

  34. Slide 34: Near-Term Anticipated Milestones

    Near-Term Anticipated Milestones Drug Candidate Event Date HIV HIV HIV 2nd Gen NNRTI (RDEA427) FIH micro-dosing / human PK results 1Q08 ? RDEA806 Phase 2a results (PoC) 2Q08 ? RDEA806 Phase 2b start 1H09 post-partnering RDEA427 Phase 1 start 1H09 post-partnering Gout Gout Gout RDEA806 Phase 2 start

  35. Slide 35: Biosciences

    Biosciences Designing Solutions for Serious Diseases NASDAQ: RDEA

Ardea Biosciences — Corporate Update (December 2008) on 6ix